Grande Enrique, Díaz Ángel, López Carlos, Munarriz Javier, Reina Juan-José, Vera Ruth, Bernárdez Beatriz, Aller Javier, Capdevila Jaume, Garcia-Carbonero Rocio, Jimenez Fonseca Paula, Trapero-Bertran Marta
Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain.
Ther Adv Endocrinol Metab. 2019 Feb 18;10:2042018819828217. doi: 10.1177/2042018819828217. eCollection 2019.
Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce.
A systematic review on the economic impact of GEP-NETs was carried out using four databases: , the and . Fully published articles from January 2000 to May 2017, in English and Spanish, were included. All articles that satisfied the inclusion criteria were included in the systematic review; summary descriptive statistics were used to describe the methodological characteristics.
The 14 studies selected included cost-of-illness analyses ( = 4), economic evaluations ( = 7) and budget impact analyses ( = 3). Almost all studies were performed in the United States. Healthcare costs for patients with NETs included medication, outpatient visits, hospitalizations, and check-ups/tests. Reducing adverse events is an area where cost savings could be achieved; however, there was not enough evidence on the cost impact of adverse events.
There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.
尽管目前在胃肠胰（GEP）神经内分泌肿瘤（NETs）治疗方法的开发方面受到关注、充满热情并取得了进展，但已发表的文献在疾病成本分析、经济评估和预算影响分析方面存在重大差距。使问题更加复杂的是，关于GEP-NETs不同诊断和治疗方式的资源利用和成本效益的数据稀缺。
使用四个数据库对GEP-NETs的经济影响进行了系统评价：[此处原文缺失数据库名称]。纳入了2000年1月至2017年5月以英文和西班牙文全文发表的文章。所有符合纳入标准的文章都纳入了系统评价；使用汇总描述性统计来描述方法学特征。
所选的14项研究包括疾病成本分析（n = 4）、经济评估（n = 7）和预算影响分析（n = 3）。几乎所有研究都是在美国进行的。NETs患者的医疗保健成本包括药物治疗、门诊就诊、住院和检查/检测。减少不良事件是一个可以实现成本节约的领域；然而，关于不良事件成本影响的证据不足。
GEP-NETs领域缺乏与资源利用相关的数据。因此，迫切需要对现有和新兴治疗方法进行成本效益和预算影响研究，以帮助NETs患者的决策过程。
